Loading...
Please wait, while we are loading the content...
Similar Documents
Amlodipine plus perindopril was better than atenolol plus bendroflumethiazide for reducing complications in hypertension.
| Content Provider | Semantic Scholar |
|---|---|
| Author | Zarnke, Kelly |
| Copyright Year | 2006 |
| Abstract | Dahlof B, Sever PS, Poulter NR, et al . Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet 2005;366:895–906. [OpenUrl][1][CrossRef][2][PubMed][3][Web of Science][4] Q In patients 40–79 years of age with hypertension and ⩾3 other cardiovascular (CV) risk factors, is amlodipine plus perindopril more effective than atenolol plus bendroflumethiazide for reducing CV outcomes? Clinical Impact Ratings GP/FP/Primary care ★★★★★☆☆ IM/Ambulatory care ★★★★★★☆ Cardiology ★★★★★★☆ ### ![Graphic][5] Design randomised controlled trial (Anglo-Scandinavian Cardiac Outcomes Trial–Blood Pressure Lowering Arm [ASCOT-BPLA]). ### ![Graphic][6] Allocation concealed.* ### ![Graphic][7] Blinding blinded (outcome assessors).* ### ![Graphic][8] Follow up period median 5.5 years. ### ![Graphic][9] Setting 686 family practices in the Nordic countries and 32 regional centres in the UK and Ireland. ### ![Graphic][10] Patients 19 257 patients 40–79 years of age (mean age 63 y, 77% men) who had hypertension and ⩾3 other CV risk factors. Exclusion criteria included previous myocardial infarction (MI), currently treated angina, and a cerebrovascular event … [1]: {openurl}?query=rft.jtitle%253DLancet%26rft.stitle%253DLancet%26rft.aulast%253DDahlof%26rft.auinit1%253DB.%26rft.volume%253D366%26rft.issue%253D9489%26rft.spage%253D895%26rft.epage%253D906%26rft_id%253Dinfo%253Adoi%252F10.1016%252FS0140-6736%252805%252967185-1%26rft_id%253Dinfo%253Apmid%252F16154016%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx [2]: /lookup/external-ref?access_num=10.1016/S0140-6736(05)67185-1&link_type=DOI [3]: /lookup/external-ref?access_num=16154016&link_type=MED&atom=%2Febmed%2F11%2F2%2F42.atom [4]: /lookup/external-ref?access_num=000231770000027&link_type=ISI [5]: /embed/inline-graphic-1.gif [6]: /embed/inline-graphic-2.gif [7]: /embed/inline-graphic-3.gif [8]: /embed/inline-graphic-4.gif [9]: /embed/inline-graphic-5.gif [10]: /embed/inline-graphic-6.gif |
| Starting Page | 42 |
| Ending Page | 42 |
| Page Count | 1 |
| File Format | PDF HTM / HTML |
| DOI | 10.1136/ebm.11.2.42 |
| Alternate Webpage(s) | http://www.acpjc.org/Content/pdf/ACPJC-2006-144-2-032.pdf |
| PubMed reference number | 17213072 |
| Alternate Webpage(s) | https://doi.org/10.1136/ebm.11.2.42 |
| Journal | Medline |
| Volume Number | 11 |
| Issue Number | 2 |
| Journal | Evidence-based medicine |
| Language | English |
| Access Restriction | Open |
| Content Type | Text |
| Resource Type | Article |